Evidence map›Paper›PMID 42591330›Full record

SynthesisFrontiers in immunology2026

Reservoir differences across HIV-1 subtypes: a systematic review to guide cure research.

Myrthe S Willemsen, Anniek A N Tanja, Sody Munsaka, Damalie Nakanjako, Thumbi Ndung'u, Maria A Papathanasopoulos, Kevin Jenniskens, Giulia Sinatti, Jori Symons, Annemarie M J Wensing and 2 more

Abstract readSystematic Review
In one paragraph

Synthesis in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Myrthe S WillemsenJulius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands.
Anniek A N TanjaTranslational Virology, Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, Netherlands.
Sody MunsakaDepartment of Biomedical Sciences, School of Health Sciences, University of Zambia, Lusaka, Zambia.
Damalie NakanjakoDepartment of Medicine, School of Medicine, Makerere University College of Health Sciences, Kampala, Uganda.
Thumbi Ndung'uAfrica Health Research Institute, Durban, South Africa.
Maria A PapathanasopoulosHIV Pathogenesis Research Unit, Department of Molecular Medicine and Haematology, Faculty of Health Sciences, University of Witswatersrand, Johannesburg, South Africa.
Kevin JenniskensJulius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands.
Giulia SinattiDepartment of Social and Cultural Anthropology, Vrije Universiteit Amsterdam, Amsterdam, Netherlands.
Jori SymonsTranslational Virology, Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, Netherlands.
Annemarie M J WensingTranslational Virology, Department of Global Public Health and Bioethics, University Medical Center Utrecht, Utrecht, Netherlands.
Monique NijhuisTranslational Virology, Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, Netherlands.
Ganna RozhnovaJulius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands.

Funding

Bill & Melinda Gates Foundation INV-033558Wellcome Trust
6 · The paper itself

Abstract

Introduction: Despite effective antiretroviral therapy, HIV-1 persists as a viral reservoir and remains a major barrier to a durable cure. Reservoir size and dynamics are central determinants of the success of cure strategies. Efforts to characterize and target the HIV-1 reservoir have primarily focused on people with HIV-1 subtype B in Western Europe and North America. This emphasis has limited our understanding of reservoir size and dynamics in individuals with non-B subtypes, which account for most infections globally, particularly in high-burden regions such as sub-Saharan Africa. This systematic review synthesizes evidence on HIV-1 reservoir size in individuals with non-B subtypes and compiles reported reservoir outcomes alongside demographic and clinical metadata. Methods: PubMed and EMBASE were searched for studies quantifying the HIV-1 reservoir in peripheral blood from individuals with non-B subtypes. Eligible studies quantified reservoir size in at least three non-B samples stratified by subtype or directly compared measurements between subtypes. Data were extracted on subtype, reservoir size, statistical comparisons thereof, and key demographic and clinical data. Study quality was assessed using a pre-defined, custom set of criteria. Data were synthesized by organizing within-study statistical comparisons by subtype in a schematic overview to indicate the direction of effect. Results: Of 1589 unique records, 40 studies quantifying HIV-1 reservoir size in individuals with non-B subtypes were included. Records excluded at full-text screening commonly lacked viral subtype determination and/or subtype-stratified outcomes. Comparisons between subtype B and pooled non-B subtypes suggest a larger reservoir for subtype B. Substantial differences in study design, (meta)data reporting, and comparability limited direct comparison across studies. Conclusion: Strengthening knowledge on the HIV-1 subtype-specific reservoir is essential for the development of effective and globally relevant cure strategies. The available data point toward possible differences in reservoir size between subtype B and non-B subtypes. To improve further assessment, we developed recommendations urging studies to use standardized subtyping methods, report viral subtype according to Los Alamos guidelines, and provide detailed individual-level outcomes and metadata, including disease stage at treatment initiation, ART duration, and viral suppression status. Furthermore, we strongly recommend using multi-subtype reservoir assays that are cross-validated to enhance comparability across studies. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251074799, identifier CRD420251074799.

Indexed as

HIV-1HIV InfectionsDisease ReservoirsHumansViral LoadVirus LatencyHIV-1HIV curehumanssubtypeviral latencyviral reservoir

Identifiers

PMID42591330
PMCPMC13461633

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.